Gilead's (GILD) Sofosbuvir FDA Panel Review Date Set for October 25th StreetInsider.com (subscription) ... manufactured by Gilead Sciences, Inc. (Nasdaq: GILD), with a proposed indication for the treatment of chronic hepatitis C infection, in combination with other agents in adult patients with genotypes 1 to 6 and/or adult patients awaiting liver ... |
